Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492

S. Buti; M. Puligandla; M. Bersanelli; R. S. DiPaola; J. Manola; S. Taguchi; N. B. Haas

doi:10.1093/annonc/mdx799

Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492

S. Buti, M. Puligandla, M. Bersanelli, R. S. DiPaola, J. Manola, S. Taguchi, N. B. Haas

Research output: Contribution to journal › Comment/debate

Abstract

This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O'Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Original language	English
Pages (from-to)	1604
Number of pages	1
Journal	Annals of Oncology
Volume	29
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdx799
State	Published - Jul 1 2018

Bibliographical note

Funding Information:
This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdx799

Fingerprint

Dive into the research topics of 'Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492'. Together they form a unique fingerprint.

Cite this

Buti, S., Puligandla, M., Bersanelli, M., DiPaola, R. S., Manola, J., Taguchi, S., & Haas, N. B. (2018). Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492. Annals of Oncology, 29(7), 1604. https://doi.org/10.1093/annonc/mdx799

@article{e77ba39011ac45c4b9cac0edcf989868,

title = "Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492",

abstract = "This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O'Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.",

author = "S. Buti and M. Puligandla and M. Bersanelli and DiPaola, {R. S.} and J. Manola and S. Taguchi and Haas, {N. B.}",

note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O{\textquoteright}Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",

year = "2018",

month = jul,

day = "1",

doi = "10.1093/annonc/mdx799",

language = "English",

volume = "29",

pages = "1604",

number = "7",

}

Buti, S, Puligandla, M, Bersanelli, M, DiPaola, RS, Manola, J, Taguchi, S & Haas, NB 2018, 'Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492', Annals of Oncology, vol. 29, no. 7, pp. 1604. https://doi.org/10.1093/annonc/mdx799

Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492. / Buti, S.; Puligandla, M.; Bersanelli, M. et al.
In: Annals of Oncology, Vol. 29, No. 7, 01.07.2018, p. 1604.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492

AU - Buti, S.

AU - Puligandla, M.

AU - Bersanelli, M.

AU - DiPaola, R. S.

AU - Manola, J.

AU - Taguchi, S.

AU - Haas, N. B.

N1 - Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Publisher Copyright: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O'Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

AB - This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O'Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820 and CA180794. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

UR - http://www.scopus.com/inward/record.url?scp=85051554799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051554799&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx799

DO - 10.1093/annonc/mdx799

M3 - Comment/debate

C2 - 29608641

AN - SCOPUS:85051554799

VL - 29

SP - 1604

IS - 7

ER -

Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this